Amgen's drugs target diseases that are serious and typically have limited treatment options.

With a presence in more than 100 countries, every year we reach millions of patients around the world.
At Amgen we take advantage of the full potential of biotechnology to collaborate and provide new tools for clinical practice.

ONCOLOGY AND HEMATOLOGY

Amgen has a portfolio of innovative products and biosimilars for the treatment of oncological and hematological diseases, such as colorectal cancer, leukemia and multiple myeloma.

INFLAMMATORY DISEASES

Amgen developed medicines in the field Of inflammation, and we are currently discovering innovative molecules to treat chronic inflammatory diseases. Some of the conditions to which we provide solutions are for autoimmune pathologies such as rheumatoid arthritis and psoriasis, which affect millions Of patients in the world. Inflammation is another field in which Amgen has biosimilars approved to improve healthcare costs in chronic diseases.

BONE DISEASES

In general medicine, Amgen is a leader in bone health with more than 20 years of osteoporosis research experience, and is committed to combating this disease to help people at high risk for fracture reduce their risk Of a first and subsequent fracture.

CARDIOVASCULAR DISEASES

In general medicine, Amgen is dedicated to addressing important scientific questions to advance care and improve the lives Of patients with cardiovascular disease, the leading cause of morbidity and mortality worldwide.

science-page-call-out
science-page-call-out-mobile

Want To Know More About What We Are Working On?

For information on the drugs that are in development, we invite you to visit our pipeline